Please assess the completion status of the following clinical trial:

Trial Title: Dose-Range Finding Study for MK0893 (0893-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy~Exclusion Criteria:~* Patients have a history of Type 1 Diabetes Mellitus~* Patients taking insulin or thiazolidinedione (TZD, a peroxisome proliferator-activated receptor \[PPAR\]-gamma agonist)~* Patients who have a contraindication to metformin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MK0893 80 mg (Type: EXPERIMENTAL): MK0893 tablets totaling 80 mg once daily.
- MK0893 60 mg (Type: EXPERIMENTAL): MK0893 tablets totaling 60 mg once daily.
- MK0893 40 mg (Type: EXPERIMENTAL): MK0893 40 mg tablet once daily.
- MK0893 20 mg (Type: EXPERIMENTAL): MK0893 20 mg tablet once daily.
- Metformin (Type: ACTIVE_COMPARATOR): Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): PLA tablets. 12 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).